Stefan Sillau

Stefan Sillau

Auto-generated profile, based on publicly available information

Stefan Sillau

Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
VFVera Fridman
Vera Fridman
SSStefan Sillau
Stefan Sillau
GAGyula Acsadi
Gyula Acsadi
CBChelsea Bacon
Chelsea Bacon
KDKimberly Dooley
Kimberly Dooley
T(the Inherited Neuropathies Consortium—Rare Diseases Clinical Research Network (INC-RDCRN)
the Inherited Neuropathies Consortium—Rare Diseases Clinical Research Network (INC-RDCRN)
Objective To evaluate the sensitivity of Rasch analysis-based, weighted Charcot-Marie-Tooth Neuropathy and Examination Scores (CMTNS-R and CMTES-R) to clinical progression in patients with Charcot-Marie-Tooth disease type 1A (CMT1A). Methods Patients with CMT1A from 18 sites of the Inherited Neuropathies Consortium were evaluated between 2009 and 2018. Weighted CMTNS and CMTES modified category responses were developed with Rasch analysis of the standard scores. Change from baseline for CMTNS-R and CMTES-R was estimated with longitudinal regression models. Results Baseline CMTNS-R and CMTES-R scores were available for 517 and 1,177 participants, respectively. Mean ± SD age of participants with available CMTES-R scores was 41 ± 18 (range 4–87) years, and 56% were female. Follow-up CMTES-R assessments at 1, 2, and 3 years were available for 377, 321, and 244 patients. A mixed regression model showed significant change in CMTES-R score at years 2 through 6 compared to baseline (mean change from baseline 0.59 points at 2 years, p = 0.0004, n = 321). Compared to the original CMTES, the CMTES-R revealed a 55% improvement in the standardized response mean (mean change/SD change) at 2 years (0.17 vs 0.11). Change in CMTES-R at 2 years was greatest in mildly to moderately affected patients (1.48-point mean change, 95% confidence interval 0.99–1.97, p < 0.0001, for baseline CMTES-R score 0–9). Conclusion The CMTES-R demonstrates change over time in patients with CMT1A and is more sensitive than the original CMTES. The CMTES-R was most sensitive to change in patients with mild to moderate baseline disease severity and failed to capture progression in patients with severe CMT1A. ClinicalTrials.gov identifier NCT01193075.

12 February 2019 in Neurology
Verified
Journal Article
Closed access
PDF file
JHJustin M. Honce
Justin M. Honce
KNKavita V. Nair
Kavita V. Nair
SSStefan Sillau
Stefan Sillau
BVBrooke Valdez
Brooke Valdez
AMAugusto Miravalle
Augusto Miravalle
TVTimothy Vollmer
Timothy Vollmer
Objective To examine whether rituximab induction followed by glatiramer acetate (GA) monotherapy is more effective than GA alone for the treatment of relapsing multiple sclerosis with active disease. Methods This was a single-center, double-blind, placebo-controlled study. Fifty-five participants were randomly assigned (1:1 ratio) to either rituximab (R-GA) or placebo (P-GA) induction, followed by GA therapy initiated in all participants. Participants were followed up to 3 years. The primary endpoint was the number of participants with no evidence of disease activity (NEDA): those without relapse, new MRI lesions, and sustained change in disability. Results Twenty-eight and 27 participants received rituximab and placebo induction, respectively, with one participant in each arm withdrawing before 6-month MRI. There were no significant differences in baseline characteristics. At end of study, 44.44% of R-GA participants demonstrated NEDA vs 19.23% of P-GA participants (p = 0.049). Treatment failed for a smaller proportion of R-GA participants (37.04% R-GA vs 69.23% P-GA, p = 0.019), and time to treatment failure was longer (23.32 months R-GA vs 11.29 months P-GA, p = 0.027). Fewer participants in the R-GA arm had new lesions (25.93% R-GA vs 61.54% P-GA, p = 0.009), and there were fewer new T2 lesions (0.48 R-GA vs 1.96 P-GA, p = 0.027). Probability of demonstrating NEDA in the R-GA arm returned to baseline within the study period. There were no differences in adverse events. Conclusions Induction therapy with rituximab followed by GA may provide superior efficacy in the short term than GA alone in relapsing multiple sclerosis, but this benefit appears to wane within the study period. Larger studies are needed to assess sustainability of results. ClinicalTrials.gov identifier NCT01569451.

1 June 2019 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
DVDaniel Vela-Duarte
Daniel Vela-Duarte
ENEric Nyberg
Eric Nyberg
SSStefan Sillau
Stefan Sillau
APAmy Pate
Amy Pate
PCPaula Castellanos
Paula Castellanos
Andrés Henao-MartinezAndrés Henao-Martinez
Andrés Henao-Martinez


1 April 2022 in Neurology Clinical Practice
Verified
Journal Article
Closed access
PDF file
BKBenzi M. Kluger
Benzi M. Kluger
NKNeha M. Kramer
Neha M. Kramer
MKMaya Katz
Maya Katz
NGNicholas B. Galifianakis
Nicholas B. Galifianakis
SPSteven Pantilat
Steven Pantilat
JHJoshua Hauser
Joshua Hauser
Despite increasing awareness of the importance of a palliative care approach to meet the needs of persons living with neurologic illness, residency and fellowship programs report meeting this educational need due to a limited pool of neuropalliative care educators and a lack of adequate educational resources. To meet this need, a group of experts in neuropalliative care and palliative medicine leveraged resources from the Education in Palliative and End-of-life Care (EPEC) program and the National Institutes of Nursing Research to create a library of modules addressing topics relevant for neurology trainees, palliative medicine fellows, and clinicians in practice. In this article, we describe the development and dissemination plan of the EPEC Neurology program, initial evidence of efficacy, and opportunities for neurology educators and health services researchers to use these resources.

1 January 2019 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
LWLaura Weinkle
Laura Weinkle
CDChristopher H. Domen
Christopher H. Domen
ISIan Shelton
Ian Shelton
SSStefan Sillau
Stefan Sillau
KNKavita Nair
Kavita Nair
EAEnrique Alvarez
Enrique Alvarez